In conclusion, in this nonrandomized controlled trial, lazertinib demonstrated substantial CNS activity regardless of the presence of T790M variants, providing an effective approach against the progression of intracranial metastases in patients with EGFR-variant NSCLC who progressed after failure of first-generation or second-generation EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.